Poster (OncoLilleDays2022) – Mechanobiological characterization of a 3D in vitro pancreatic ductal adenocarcinoma model and the study of tumor-stroma interaction

Thomas Meynard, PhD student in OncoLille (under the supervision of Vincent Senez and Isabelle Van Seuningen) in collaboration with HCS Pharma too, presented a poster showing that it is possible to include BIOMIMESYS® in a microfluidic chip to co-culture Cancer-Associated fibroblasts and cancerous cells, with the aim to increase the Read more…

Poster – Including the matricial tumoral microenvironment in 3D in vitro models by using a Hyaluronic-Acid-based hydroscaffold™

Abstract: In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and Read more…

Poster – (ECM 2022) Development of innovative hiPSC-based model including an innovative 3D modified hyaluronic acid hydroscaffold for phenotypic screening

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to studymetabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and Read more…

Poster – A single procedure to generate functional hiPSCs-derived liver organoids -Towards an innovative tool suitable for drug screening

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of Read more…

Poster – BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physiological organs-on-chip (OoC)

How to make in vitro models predictive of in vivo conditions? Dynamic models hold promise for future predictive microphysiological systems (MPS). By combining BIOMIMESYS® as an ECM surrogate for 3D culture, and hiPSC-derived cells, these dynamic microfluidic systems will revolutionize the field, reproducing human tissues and predict human outcomes.

Poster – Development and automation of 3D innovative hiPSC-based liver organoids including the microenvironment for phenotypic screening – Application on metabolic diseases – version DHU2020

Ask for high quality link by putting your email below We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in Read more…

Poster – Development and automation of 3D innovative hiPSC-based liver organoids including the microenvironment for phenotypic screening – Application on metabolic diseases

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of Read more…

Poster – Development of a new liver-on-chip including BIOMIMESYS® technology for mimicking the liver extracellular matrix: first results and perspectives

Objective: to develop a new liver-on-chip model that includes a relevant 3D matrix for hepatic cell growth and function with the use of of BIOMIMESYS® Liver hydroscaffold for a physiological 3D hepatocyte culture. Ask for high quality link by putting your email below View and download on Slideshare (low quality) Read more…

Poster – Impact of the composition and stiffness of a 3D hyaluronic acid-based hydroscaffold on breast cancer cell growth and CD44 expression

Ask for high quality link by putting your email below The extracellular matrix (ECM) is present in all solid tissues and is a master regulator of cell behavior and phenotype. The ECM in each tissue is characterized by its biochemical and biophysical properties, which are modified in many different types Read more…

Poster – A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffold

Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy.  What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ? Ask for a high quality version of this poster : View and download on Slideshare (low quality) https://fr.slideshare.net/hcspharma/a-groundbreaking-3d-cell-culture-technology-for-hcs-biomimesys-hydroscaffold

Poster – Characterisation of 3D cultured primary human hepatocytes and HepaRG for DMSO-free preclinical toxicity testing

Ask for high quality link by entering your email below Hepatocytes in primary cultures are still the gold standard in the pharmaceutical industry ; however they are expensive and have a very short lifespan with a progressive loss of specific functions over time. The dipolar aprotic solvent, dimethyl sulfoxide (DMSO) Read more…

Poster – Urine sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia

Human induced pluripotent stem cells (hiPSC) are becoming a relevant model for the study of liver metabolic diseases once differentiated into hepatocyte-like cells (HLC), and it has been shown that they can faithfully recapitulate autosomal dominant hypercholesterolemia (ADH). PCSK9 is a critical modulator of cholesterol homeostasis, and quickly became a Read more…

Poster – In vitro dermocosmetology : high content analysis approach using human primary keratinocytes and fibroblasts

Cell biology is part of the R&D activity in dermocosmetology, as providers of active extracts or pure compounds have to demonstrate their efficacy and safety. At HCS Pharma, we are developing new dermocosmetology assays on relevant cellular models, like human primary keratinocytes and human primary fibroblasts, using our automated platform and high content analysis system.